Orsini Specialty Pharmacy is proud to offer patients with severe homozygous cystinuria the first available generic version of THIOLA® (tiopronin). The...
Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases, gene therapies, and complex conditions, announced that...
Alzheimer’s disease is the most common type of dementia. It is an irreversible, degenerative brain disorder that slowly destroys memory, language,...
At Orsini Specialty Pharmacy, we provide our patients with both the clinical and administrative support necessary to help manage the treatment of their...
Hereditary Angioedema (HAE) is a very rare and potentially life-threatening genetic condition. HAE involves recurring attacks of severe swelling...
Mucopolysaccharidosis (MPS) is a rare disease in which the body is missing or does not have enough of an enzyme needed to break down long chains of...
This past year has shone a harsh light on some of our healthcare system’s most glaring flaws, illuminating a divide too deep to be ignored. Limited...
We are honored to share the third patient story in our "All the Difference" series, where extraordinary individuals share their experiences living with...
This blog was written by Karen Murphy, Patient Assistance Liaison at Orsini Specialty Pharmacy It’s an unfortunate truth that although incredible...
We are honored to share the second eBook in our "All the Difference" series, where extraordinary individuals share their experiences living with rare...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
Orsini Selected by BioMarin to Dispense ROCTAVIAN™, the First Gene Therapy for the Treatment of Severe Hemophilia A
Optimizing Patient Care Services with Rare Disease Limited Distribution Drugs
Orsini Selected by Sarepta Therapeutics to Dispense ELEVIDYS (delandistrogene moxeparvovec-rokl), the First Gene Therapy to Treat Duchenne Muscular Dystrophy
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)